Tag Archives: products:

Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019

by Anders Olsen, Reed F. Beall, Ryan P. Knox, Sean S. Tu, Aaron S. Kesselheim, William B. Feldman Background Insulin is the primary treatment for type 1 and some type 2 diabetes but remains costly in the United States, even … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , | Comments Off on Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019